Open AccessActivities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria
Author(s) -
Thalia I. Nicas,
D. L. Mullen,
J. E. Flokowitsch,
David A. Preston,
Nancy Snyder,
Robert E. Stratford,
R. D. G. Cooper
Publication year - 1995
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.39.11.2585
Subject(s) - teicoplanin , glycopeptide , glycopeptide antibiotic , vancomycin , microbiology and biotechnology , enterococcus , vancomycin resistant enterococci , antibiotics , biology , bacteria , antibacterial agent , streptococcaceae , staphylococcus aureus , genetics
LY191145 is the prototype of a series of compounds with activities against vancomycin-resistant enterococci derived by modification of the glycopeptide antibiotic LY264826. LY191145 had MICs for vancomycin- and teicoplanin-resistant enterococci of < or = 4 micrograms/ml for 50% of isolates and < or = 16 micrograms/ml for 90% of isolates. Its MICs for vancomycin-resistant, teicoplanin-susceptible enterococci were 1 to 8 micrograms/ml. LY191145 retains the potent activities of its parent compound against staphylococci and streptococci. In vivo studies in a mouse infection model confirmed these activities. This compound indicates the potential of semisynthetic glycopeptides as agents against antibiotic-resistant gram-positive bacteria.